NewLink Genetics (NLNK) Reaches $6.51 After 8.00% Down Move; Blackrock Muniyield Michigan Quality Fund (MIY) Has 0.86 Sentiment

February 13, 2018 - By Winifred Garcia

The stock of NewLink Genetics Corporation (NASDAQ:NLNK) is a huge mover today! The stock decreased 5.86% or $0.4 during the last trading session, reaching $6.51. About 496,555 shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has risen 49.90% since February 13, 2017 and is uptrending. It has outperformed by 33.20% the S&P500.The move comes after 8 months negative chart setup for the $241.37M company. It was reported on Feb, 13 by Barchart.com. We have $5.99 PT which if reached, will make NASDAQ:NLNK worth $19.31M less.

The stock increased 0.15% or $0.02 during the last trading session, reaching $13.35. About 1,671 shares traded. BlackRock MuniYield Michigan Quality Fund, Inc. (MIY) has declined 6.97% since February 13, 2017 and is downtrending. It has underperformed by 23.67% the S&P500.

Investors sentiment increased to 1.22 in 2017 Q3. Its up 0.28, from 0.94 in 2017Q2. It increased, as 15 investors sold NewLink Genetics Corporation shares while 30 reduced holdings. 25 funds opened positions while 30 raised stakes. 18.44 million shares or 16.63% more from 15.81 million shares in 2017Q2 were reported. Artal Grp Sa holds 150,000 shares or 0.03% of its portfolio. 311,927 were accumulated by Ameriprise Financial Inc. 21,584 were accumulated by Citadel Advsr Limited Liability Company. Rock Springs Cap L P has invested 0.03% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Endurant Cap Mgmt L P has 36,100 shares for 0.11% of their portfolio. Fund Management Sa reported 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Highbridge Management Llc has invested 0.01% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Moreover, Nationwide Fund Advisors has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK). Dimensional Fund L P holds 78,093 shares or 0% of its portfolio. Rhenman Prtn Asset Mgmt invested 0.13% in NewLink Genetics Corporation (NASDAQ:NLNK). Vanguard Group invested in 0% or 1.02M shares. Redmile Group Ltd Liability holds 0.63% or 1.25M shares in its portfolio. Geode Cap Mgmt Ltd Liability reported 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Qs Limited Liability Company accumulated 139,507 shares or 0.01% of the stock. Trexquant Investment L P stated it has 0.04% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK).

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on February, 27. They expect $-0.69 earnings per share, down 50.00% or $0.23 from last year’s $-0.46 per share. After $-0.69 actual earnings per share reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 6 analysts covering NewLink Genetics (NASDAQ:NLNK), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NewLink Genetics had 15 analyst reports since March 23, 2016 according to SRatingsIntel. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) earned “Buy” rating by Jefferies on Friday, September 8. Cantor Fitzgerald maintained NewLink Genetics Corporation (NASDAQ:NLNK) rating on Sunday, June 4. Cantor Fitzgerald has “Buy” rating and $3200 target. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) earned “Buy” rating by Stifel Nicolaus on Monday, July 10. The rating was downgraded by SunTrust on Wednesday, May 11 to “Neutral”. Jefferies maintained the stock with “Hold” rating in Thursday, August 24 report. Robert W. Baird maintained NewLink Genetics Corporation (NASDAQ:NLNK) on Friday, October 13 with “Buy” rating. The stock has “Outperform” rating by Robert W. Baird on Wednesday, March 23. SunTrust upgraded NewLink Genetics Corporation (NASDAQ:NLNK) on Thursday, March 30 to “Buy” rating. On Friday, September 8 the stock rating was upgraded by Robert W. Baird to “Outperform”. Jefferies maintained NewLink Genetics Corporation (NASDAQ:NLNK) on Thursday, June 8 with “Hold” rating.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $241.37 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>